Johnson & Johnson (JNJ)
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (87%) **Content type:** Clinical